Alembic Pharma Q2 PBT at Rs 45.04 cr

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 24% increase in revenues to Rs 398.05 crores for the quarter ended 30th September 2011, compared to Rs 321.17 crores in the corresponding quarter last year.

The Company posted an impressive 47% growth in profit before tax at Rs 45.04 crores for the quarter ended September 2011 against Rs 30.60 crores posted in corresponding quarter last fiscal.

EBIDTA margins for quarter ended September 11 up at 15.19%
from 13.21% for corresponding quarter last year.

International Business

International Generics to the regulated markets grew by 79% to Rs. 71.38 crores from Rs. 39.79 Crores over the corresponding quarter last year.

Formulations sales to ROW markets amounted to Rs. 12.04 crores against Rs. 14.95 crores in corresponding quarter last year.

Export of API products grew by 50% to Rs. 60.44 crores from Rs. 40.41 crores over corresponding quarter last year. Cumulative DMF filings at 56. Cumulative ANDA filings at 41. Cumulative ANDA approvals now stands at 15.

Domestic Formulation Business

The domestic formulation business posted sales of Rs. 226.92 crores against Rs. 206.83 crores registering 10% growth over the corresponding quarter last year.

Alembic has maintained a market share of 1.86%. The positive impact of the restructuring undertaken in the recent past is evident from the encouraging numbers.

Alembic has four brands in the list of top 300 brands of the industry i.e.

Read More